Investor's Champion
How to make your money go further

The Ten Bagger Quest

25/04/2016

Massive potential from drug development
By Michael Crockett

This drug discovery company has recently stated that it is increasingly confident that its lead product should be of considerable benefit to millions of patients worldwide. Perhaps this is part of the reason that its shares have shot up by 50% in the last few weeks.

AimZine explains why this company has good reason to be confident of future success and considers the financial implications of such success.

Follow Investors Champion’s comments on small caps daily on the Investors Champion Blog.

NOTE: This article is copyright of Investors Champion. No part should be copied, reproduced or distributed in any way without prior consent.

Synairgen (AIM: SNG) http://www.synairgen.com/ Introduction Synairgen is a drug discovery company founded by three professors from the University of Southampton. The Company is based at Southampton General Hospital. Synairgen’s focus is on developing new treatments for severe respiratory conditions. Over a 10 year period the Company has invested considerable time and money in developing its lead product, inhaled Interferon Beta (IFN-Beta), for use by Asthma and COPD patients, particularly when they have been affected by a cold virus. In June 2014 Synairgen successfully licensed this lead product to AstraZeneca in a deal which has the potential to earn the Company…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login